179 related articles for article (PubMed ID: 31794095)
1. Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.
Rausch CR; Jabbour EJ; Kantarjian HM; Kadia TM
Cancer; 2020 Mar; 126(6):1152-1160. PubMed ID: 31794095
[No Abstract] [Full Text] [Related]
2. Cytarabine induced noncardiogenic pulmonary edema in a case of acute lymphoblastic leukemia.
Yegin ZA; Aki S; Sucak G; Yagci M
Int J Lab Hematol; 2007 Dec; 29(6):482-3. PubMed ID: 17988309
[No Abstract] [Full Text] [Related]
3. Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia.
Kantarjian HM
Clin Adv Hematol Oncol; 2019 May; 17(5):268-270. PubMed ID: 31188803
[No Abstract] [Full Text] [Related]
4. Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia.
Jonas BA; Fisch SC; Rosenberg AS; Hoeg RT; Tuscano JM; Abedi M
Am J Hematol; 2021 Apr; 96(4):E114-E117. PubMed ID: 33476436
[No Abstract] [Full Text] [Related]
5. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
Romaguera JE; Wang M; Feng L; Fayad LE; Hagemeister F; McLaughlin P; Rodriguez MA; Fanale M; Orlowski R; Kwak LW; Neelapu S; Oki Y; Pro B; Younes A; Samaniego F; Fowler N; Hartig K; Valentinetti M; Smith J; Ford P; Naig A; Medeiros LJ; Kantarjian HM; Goy A
Cancer; 2018 Jun; 124(12):2561-2569. PubMed ID: 29723393
[TBL] [Abstract][Full Text] [Related]
6. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
Jabbour E; O'Brien S; Kantarjian H; Garcia-Manero G; Ferrajoli A; Ravandi F; Cabanillas M; Thomas DA
Blood; 2007 Apr; 109(8):3214-8. PubMed ID: 17209054
[TBL] [Abstract][Full Text] [Related]
7. Re: Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
Chamberlain MC; Glantz MJ
Blood; 2007 Sep; 110(5):1698; author reply 1698-9. PubMed ID: 17712051
[No Abstract] [Full Text] [Related]
8. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
[TBL] [Abstract][Full Text] [Related]
9. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
10. The hyper-CVAD regimen in adult acute lymphocytic leukemia.
Garcia-Manero G; Kantarjian HM
Hematol Oncol Clin North Am; 2000 Dec; 14(6):1381-96, x-xi. PubMed ID: 11147229
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
Romaguera JE; Fayad LE; McLaughlin P; Pro B; Rodriguez A; Wang M; Weaver P; Hartig K; Kwak LW; Feldman T; Smith J; Ford P; Goldberg S; Pecora A; Goy A
Br J Haematol; 2010 Oct; 151(1):47-53. PubMed ID: 20735402
[TBL] [Abstract][Full Text] [Related]
12. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Short NJ; Jabbour E; Sasaki K; Patel K; O'Brien SM; Cortes JE; Garris R; Issa GC; Garcia-Manero G; Luthra R; Thomas D; Kantarjian H; Ravandi F
Blood; 2016 Jul; 128(4):504-7. PubMed ID: 27235138
[TBL] [Abstract][Full Text] [Related]
13. Progressive paresthesia and weakness after intrathecal chemotherapy.
Marshall R; Gupta ND; Palacios E; Neitzschman HR
J La State Med Soc; 2008; 160(2):92-4. PubMed ID: 18681351
[TBL] [Abstract][Full Text] [Related]
14. [Transverse leukonychia and anti-leukemia chemotherapy].
Bader-Meunier B; Garel D; Dommergues JP; Venencie PY
Ann Pediatr (Paris); 1990 May; 37(5):337-8. PubMed ID: 2369052
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of AIEOP-8805 protocol for acute B-cell lymphoblastic leukemia of childhood.
Pillon M; Aricò M; Basso G; Locatelli F; Citterio M; Micalizzi C; Testi AM; Barisone E; Nardi M; Lombardi A; Rondelli R; Rosolen A;
Pediatr Blood Cancer; 2011 Apr; 56(4):544-50. PubMed ID: 21298738
[TBL] [Abstract][Full Text] [Related]
16. A unique breast involvement detected by MRI-DWIBS in T cell acute lymphoblastic leukemia.
Katagiri S; Azuma K; Akahane D; Saito K; Ohyashiki K
Breast J; 2019 Nov; 25(6):1276-1277. PubMed ID: 31301079
[No Abstract] [Full Text] [Related]
17. Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.
Garg R; Kantarjian H; Thomas D; Faderl S; Ravandi F; Lovshe D; Pierce S; O'Brien S
Cancer; 2009 May; 115(10):2147-54. PubMed ID: 19298009
[TBL] [Abstract][Full Text] [Related]
18. Dental abnormalities in children after chemotherapy treatment for acute lymphoid leukemia.
Minicucci EM; Lopes LF; Crocci AJ
Leuk Res; 2003 Jan; 27(1):45-50. PubMed ID: 12479851
[TBL] [Abstract][Full Text] [Related]
19. No major cognitive impairment in young children with acute lymphoblastic leukemia using chemotherapy only: a prospective longitudinal study.
Kingma A; Van Dommelen RI; Mooyaart EL; Wilmink JT; Deelman BG; Kamps WA
J Pediatr Hematol Oncol; 2002 Feb; 24(2):106-14. PubMed ID: 11990695
[TBL] [Abstract][Full Text] [Related]
20. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol.
Patte C; Sakiroglu C; Ansoborlo S; Baruchel A; Plouvier E; Pacquement H; Babin-Boilletot A;
Ann Oncol; 2002 May; 13(5):789-95. PubMed ID: 12075750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
